Search

Displaying results 2651 - 2660 of 7540 in total
  1. Drug

    Brincidofovir

    go.drugbank.com/drugs/DB12151
    ApprovedInvestigational

    Brincidofovir, developed by Chimerix under the brand name Tembexa, was approved by the FDA for the treatment of smallpox infection in June 2021. … The approval was granted under the agency’s Animal Rule,[L34480] which allows for a drug to be approved based on the results of well-controlled animal studies when human trials would be unethical or infeasible

  2. Drug

    Glatiramer

    go.drugbank.com/drugs/DB05259
    ApprovedInvestigational

    [A248880] It was approved by the FDA in 1996, and a generic version became available in 2017. … Glatiramer acetate exhibits several immunomodulatory effects and reduces the relapse rate of relapsing-remitting multiple sclerosis (RRMS) by 30%.

  3. Drug

    Abarelix

    go.drugbank.com/drugs/DB00106
    ApprovedWithdrawn

    Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis.

  4. Drug

    Promethazine

    go.drugbank.com/drugs/DB01069
    ApprovedInvestigational

    Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. … [A189901] Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSynonyms: N,N,α-trimethyl-10H-phenothiazine-10-ethanamine, N,N,alpha-trimethyl-10H-phenothiazine-10-ethanamine
  5. Drug

    Muromonab

    go.drugbank.com/drugs/DB00075
    ApprovedInvestigationalWithdrawn

    Murine monoclonal antibody specific to CD3 T-cell lymphocyte antigens. … More specifically it is a purified murine (mouse) monoclonal antibody, directed against the CD3 (T3) receptor on the surface of human T-cells (T-lymphocytes) cultured using the murine ascites method.

  6. Drug

    Methoxyflurane

    go.drugbank.com/drugs/DB01028
    ApprovedInvestigationalVet approvedWithdrawn

    If so employed, it should be administered with nitrous oxide to achieve a relatively light level of anesthesia, and a neuromuscular blocking agent given concurrently to obtain the desired degree of muscular

  7. Drug

    Efalizumab

    go.drugbank.com/drugs/DB00095
    ApprovedWithdrawn

    Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. … It was later withdrawn in 2009 due to a potential risk of progressive multifocal leukoencephalopathy (PML).[L43797]

  8. Drug

    Ketoconazole

    go.drugbank.com/drugs/DB01026
    ApprovedInvestigational

    [A188054,A188057] These effects combined with waning efficacy led to its eventual replacement by triazole agents, [fluconazole], [itraconazole], [voriconazole], and [posaconazole]. … [A181802,T116] Ketoconazole was first approved in an oral formulation for systemic use by the FDA in 1981.

  9. Drug

    Tafluprost

    go.drugbank.com/drugs/DB08819
    Approved

    Tafluprost was approved for use in the U.S. on February 10, 2012. … A prostaglandin analogue ester prodrug used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension.

  10. Drug

    Cilostazol

    go.drugbank.com/drugs/DB01166
    ApprovedInvestigational

    It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions.